

Date: 11th December, 2021

To, BSE Limited Corporate Relationship Department, 25 th Floor, P J Towers, Dalal Street, Fort, Mumbai – 400001 Scrip Code: 533259	To, National Stock Exchange of India Ltd. Exchange Plaza 5 th Floor, Plot No C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 Scrip Code: SASTASUNDR
--	--

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is further to our media release titled “*Flipkart to enter the healthcare sector through Flipkart Health+, aims to provide consumers access to affordable and convenient healthcare*” and an earlier **disclosure letter dated 19th November 2021** issued by the Company in connection with signing of definitive agreements by the Company’s subsidiary, for: (a) the sale of shares of Sastasundar Marketplace Limited (“**SML**”) which is a step-down subsidiary (i.e., subsidiary of a subsidiary) of the Company by its subsidiary, namely, Sastasundar Healthbuddy Limited (“**SHBL**”); and (b) issuance of shares by SML. In the above-referred disclosure letter, it was, inter alia mentioned that subject to the satisfaction of conditions precedent as provided in the definitive agreements and necessary approvals, the proposed transaction should be effective on or before 17th December, 2021.

We are pleased to inform that, after satisfaction of the conditions precedent as provided in the definitive agreements, that SML, a step-down subsidiary of the Company, pursuant to a combination of primary infusion and secondary transfers of its shares, has now become a subsidiary of Flipkart Health Private Limited. Pursuant to the above transaction: (a) SML has received the amount of **INR 372.00 crores** from Flipkart Health Private Limited on account of allotment of equity shares of SML to Flipkart Health Private Limited; and (b) SHBL, a subsidiary of the Company, has also received **INR 689.76 crores** from Flipkart Health Private Limited on account of transfer of equity shares of SML, as per the definitive agreements.



SASTASUNDAR VENTURES LIMITED

Azimganj House, 2nd Floor,
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),
Kolkata 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335
Email: info@sastasundar.com; Website: www.sastasundarventures.com
CIN: L65993WB1989PLC047002

Consequent to the consummation of the above transaction, Flipkart Health Private Limited holds 75.1% of equity share capital of SML and the balance 24.9% of equity share capital of SML shall continue to held by SHBL.

Further, in continuation to our disclosure made on the closure of the trading window, we further inform that the trading window of the Company for dealing in securities of the Company shall remain closed till 48 hours from this disclosure.

This is for your information and dissemination on your website.

Thanking You,

Yours Faithfully,

For Sastasundar Ventures Limited

Pratap Singh 

Pratap Singh
Company Secretary and Compliance Officer